Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Motzer

Showing results (31-40 of 155) with videos related to

Pageof 16
Sort By:
The Urologic Clinics of North America|September 5, 1998
Risk assessment for metastatic testis cancerJ A McCaffrey, D F Bajorin, R J Motzer
Cancer Treatment Reports|February 1, 1987
Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatinR J Motzer, G J Bosl, K Tauer, et al.
British Journal of Cancer|February 9, 2006
Targeted therapy for metastatic renal cell carcinomaP H Patel, R S K Chaganti, R J Motzer
Journal of the National Cancer Institute|September 7, 2000
Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose settingM Mazumdar, A Smith, W P Tong, et al.
Seminars in Oncology|April 1, 1992
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumorsD F Bajorin, H Herr, R J Motzer, et al.
Journal of the National Cancer Institute|October 19, 1994
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol designT C Chou, R J Motzer, Y Tong, et al.
Current Problems in Cancer|July 1, 1997
Renal cell carcinomaR J Motzer, P Russo, D M Nanus, et al.
Seminars in Oncology|April 18, 2000
Novel investigative approaches for advanced renal cell carcinomaW J Berg, C R Divgi, D M Nanus, et al.
Investigational New Drugs|September 20, 2001
Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinomaW J Berg, L Schwartz, R Yu, et al.
The Urologic Clinics of North America|November 1, 1994
The management of patients with advanced germ cell tumors. Seminoma and nonseminomaT M Law, R J Motzer, D F Bajorin, et al.
Pageof 16

Showing results (31-40 of 155) with videos related to

Sort By:
Pageof 16
The Urologic Clinics of North America|September 5, 1998
Risk assessment for metastatic testis cancerJ A McCaffrey, D F Bajorin, R J Motzer
Cancer Treatment Reports|February 1, 1987
Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatinR J Motzer, G J Bosl, K Tauer, et al.
British Journal of Cancer|February 9, 2006
Targeted therapy for metastatic renal cell carcinomaP H Patel, R S K Chaganti, R J Motzer
Journal of the National Cancer Institute|September 7, 2000
Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose settingM Mazumdar, A Smith, W P Tong, et al.
Seminars in Oncology|April 1, 1992
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumorsD F Bajorin, H Herr, R J Motzer, et al.
Journal of the National Cancer Institute|October 19, 1994
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol designT C Chou, R J Motzer, Y Tong, et al.
Current Problems in Cancer|July 1, 1997
Renal cell carcinomaR J Motzer, P Russo, D M Nanus, et al.
Seminars in Oncology|April 18, 2000
Novel investigative approaches for advanced renal cell carcinomaW J Berg, C R Divgi, D M Nanus, et al.
Investigational New Drugs|September 20, 2001
Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinomaW J Berg, L Schwartz, R Yu, et al.
The Urologic Clinics of North America|November 1, 1994
The management of patients with advanced germ cell tumors. Seminoma and nonseminomaT M Law, R J Motzer, D F Bajorin, et al.
Pageof 16